Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market size will reach US$ 50470 million by 2031.
Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), is a disease caused by excessive accumulation of fat in the liver.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industry Forecast” looks at past sales and reviews total world Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics sales in 2024, providing a comprehensive analysis by region and market sector of projected Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics sales for 2025 through 2031. With Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Therapeutics
Diagnostics
Segmentation by Application:
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals
Please note: The report will take approximately 2 business days to prepare and deliver.
Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), is a disease caused by excessive accumulation of fat in the liver.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industry Forecast” looks at past sales and reviews total world Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics sales in 2024, providing a comprehensive analysis by region and market sector of projected Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics sales for 2025 through 2031. With Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Therapeutics
Diagnostics
Segmentation by Application:
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
86 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Player
- 4 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
